Tesamorelin (Egrifta): Uses, Evidence and Safety

Tesamorelin is a synthetic, stabilised analogue of human growth-hormone-releasing hormone, approved by the FDA in November 2010 and sold under the brand name Egrifta. It is the only GHRH analogue ever to reach and hold full regulatory approval, which makes it the regulatory and evidence benchmark for its entire compound class.

Structurally, tesamorelin is a 44-amino-acid peptide based on the natural sequence of GHRH(1-44), with a trans-3-hexenoyl group added to the N-terminus. That single chemical modification slows enzymatic breakdown and extends the molecule’s half-life enough to make once-daily dosing practical. Because tesamorelin is a peptide therapeutic, it is regulated in the United States as a biologic: every formulation change has been cleared through a Biologics License Application (BLA) or supplemental BLA, not the small-molecule drug pathway used for compounds like MK-677.

This is the central point that separates tesamorelin from most compounds discussed in peptide circles. Sermorelin and CJC-1295 are GHRH-pathway peptides too, but they sit in a regulatory grey zone of compounding rules and research-chemical sales. Tesamorelin is a fully approved prescription medicine with a defined label, a named manufacturer, and a single sanctioned indication.

Egrifta, Egrifta SV and Egrifta WR

Tesamorelin has been sold under three brand formulations as the product has been refined. The original Egrifta (the F1 formulation) launched in the United States in January 2011 and required refrigeration. Egrifta SV (the F4 formulation) was approved in November 2018 and launched in 2019, offering room-temperature storage, a single vial, and a smaller injection volume. The newest version, Egrifta WR (the F8 formulation), was approved on 25 March 2025 and became available in September 2025. Egrifta WR is still injected daily but needs reconstitution only once weekly and uses less than half the administration volume of Egrifta SV, while remaining pharmacokinetically bioequivalent to the original product. It is patent protected in the United States until 2033 and is set to replace Egrifta SV.

The bottom line: Tesamorelin (Egrifta) is the only FDA-approved GHRH analogue, regulated as a biologic for a single HIV indication.

Tesamorelin works by binding the GHRH receptor on somatotroph cells in the anterior pituitary, prompting the gland to produce and release more of the body’s own growth hormone in a natural, pulsatile pattern. It does not supply growth hormone directly. Instead it amplifies the upstream signal, which preserves the physiological feedback loops that switch hormone release off when levels are high. This is the key mechanistic difference from injecting recombinant growth hormone, which floods the system with hormone regardless of feedback.

Raising endogenous growth hormone in turn raises insulin-like growth factor 1 (IGF-1), the downstream hormone responsible for many of growth hormone’s effects on fat metabolism and lean tissue. In people with HIV and lipodystrophy, who often have blunted growth-hormone secretion alongside abnormal fat distribution, restoring that signal preferentially mobilises visceral (deep abdominal) fat.

How tesamorelin differs from injected growth hormone

Tesamorelin is sometimes confused with recombinant human growth hormone (rhGH), but the two act in opposite directions. Injected rhGH supplies the hormone from outside the body, overriding the pituitary’s own output and the feedback loops that normally limit it. Tesamorelin instead prompts the pituitary to release more of the body’s own hormone in its natural pulses, so secretion still switches off when levels are high. For HIV-associated visceral fat specifically, high-dose rhGH was used earlier but carried a heavier metabolic and side-effect burden, including more pronounced glucose elevation and fluid retention, which is part of why a GHRH-analogue approach was developed. The trade-off is that tesamorelin produces a more modest, physiological rise rather than the supraphysiological peaks rhGH can reach.

Tesamorelin sits in the same broad family as the ghrelin-mimetic secretagogues but acts through a different receptor: tesamorelin, sermorelin and CJC-1295 are GHRH-receptor agonists, whereas ipamorelin and MK-677 act on the ghrelin (GHS-R1a) receptor. Those mechanistic differences, and how the wider class compares, are set out in the related compounds section below.

The bottom line: Tesamorelin stimulates the pituitary to release the body’s own growth hormone, preferentially reducing visceral abdominal fat.

Tesamorelin’s evidence base is unusually strong for a GHRH-pathway compound because it had to clear the FDA’s approval bar. The pivotal Phase 3 programme, led by Julian Falutz and colleagues and published in the New England Journal of Medicine in 2007, showed that tesamorelin reduced visceral adipose tissue by roughly 15% versus placebo in adults with HIV-associated abdominal fat accumulation. Those trials, sustained over 52 weeks in pooled analyses, formed the basis of the original approval. This is genuine Phase 3 randomised controlled trial evidence in humans, a tier above the preclinical or single-trial data that supports most peptides in this space.

The liver-disease research line

The most important research development beyond the original indication is tesamorelin’s effect on fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) affects an estimated 30 to 40% of people living with HIV, a higher and more aggressive burden than in the general population. In a randomised, double-blind, multicentre trial published in The Lancet HIV in 2019, a team led by Takara Stanley and Steven Grinspoon at Massachusetts General Hospital and the NIH’s National Institute of Allergy and Infectious Diseases showed that tesamorelin reduced liver fat and prevented the progression of liver fibrosis over one year in people with HIV and NAFLD. The investigators described it as the first strategy shown to be effective against NAFLD in this population, and follow-up work in JCI Insight mapped favourable shifts in the liver’s transcriptomic signature.

Visceral fat and cardiovascular risk

Theratechnologies’ VAMOS study has added observational evidence that excess visceral abdominal fat independently drives cardiovascular risk in people with HIV, reinforcing the clinical rationale for treating it. Observational data sits below RCT evidence on the quality ladder, but it strengthens the broader case that the visceral fat tesamorelin targets is a meaningful health problem rather than a cosmetic one.

What happens when treatment stops

One limitation defines how tesamorelin is used: its benefit lasts only as long as treatment continues. In the pivotal programme, patients who responded in the first six months and were then switched to placebo re-accumulated visceral fat over the following six months, while those who stayed on tesamorelin held their reduction. The drug manages visceral adiposity rather than curing it, which is why it is studied and prescribed as ongoing maintenance rather than a short course. That open-ended use is also why the monthly cost carries so much weight in any real-world decision.

The bottom line: Tesamorelin’s visceral-fat reduction reverses if treatment stops, so it works as ongoing maintenance, not a one-off course.

Study	Population	Key Finding	Evidence Tier
Falutz et al., NEJM 2007 (pivotal)	Adults with HIV lipodystrophy	~15% reduction in visceral fat vs placebo	Phase 3 RCT
Stanley et al., Lancet HIV 2019	HIV with fatty liver disease	Reduced liver fat, slowed fibrosis over 12 months	RCT (NIH-funded)
VAMOS study	Adults with HIV	Visceral fat independently linked to cardiovascular risk	Observational
Egrifta WR review (FDA, 2025)	Pharmacokinetic	F8 formulation bioequivalent, weekly reconstitution	PK study

The bottom line: Tesamorelin has Phase 3 RCT evidence for visceral fat and emerging human RCT data for HIV-related fatty liver disease.

Tesamorelin is approved and prescribable in the United States, but its legal picture elsewhere is more restrictive, and it is banned outright in competitive sport. The table below summarises its status across the three markets PeptideGuider tracks most closely.

Jurisdiction	Status	Detail
United States	Approved (prescription)	FDA-approved for HIV lipodystrophy; sold as Egrifta WR
United Kingdom	Prescription-only, no UK licence	Egrifta holds no UK marketing authorisation; supplied only as an unlicensed medicine
Australia	Schedule 4	Prescription-only medicine; not legal to supply without authority
Sport (WADA)	Prohibited at all times	Listed under S2.2.4 growth hormone releasing factors

A separate market exists in compounded and research-grade tesamorelin sold through telehealth clinics and online vendors, often for off-label fat-loss or growth-hormone-optimisation goals. That market runs on the same 503A and 503B compounding rules that reshaped the compounded GLP-1 trade, and on research-use-only sales that sit outside human-use approval entirely. Both are distinct from the approved Egrifta product. The mechanics of peptide compounding categories are explained in our Category 1 vs Category 2 guide, with current movement tracked in the reclassification tracker. For verifying any non-branded vial, our certificate of analysis guide covers what a legitimate mass-spec report should show. The wider legal position in each market is set out in our guides to peptide legality in the US, UK and Australia.

The bottom line: Only Egrifta is FDA-approved tesamorelin; compounded and research-grade versions are a separate, unapproved market.

Tesamorelin’s most commonly reported adverse reactions are arthralgia (joint pain), injection-site reactions such as redness and itching, fluid retention, and raised blood glucose. These are consistent with the effects of elevated growth hormone, and they mean blood sugar is monitored during treatment, particularly in people with or at risk of diabetes.

Because tesamorelin raises growth hormone and IGF-1, its label carries the cautions that apply across the growth-hormone axis. It is not used in people with active malignancy, since IGF-1 can theoretically promote tumour growth, and it is contraindicated where there is disruption of the hypothalamic-pituitary axis from surgery, radiation, trauma or tumour. It should not be used during pregnancy. These are label-level restrictions for a monitored prescription drug, not anecdotal cautions.

The bottom line: Tesamorelin’s main side effects are joint pain, fluid retention, injection-site reactions and raised blood glucose.

Branded Egrifta is expensive. Without insurance, monthly costs are widely reported to exceed roughly 3,000 US dollars, and insurance coverage is generally tied to the approved HIV-lipodystrophy indication and often requires prior authorisation. Manufacturer and patient-assistance programmes can reduce the out-of-pocket cost for eligible patients with the qualifying diagnosis.

This pricing structure is the practical reason tesamorelin is rarely used off-label through legitimate channels: a prescriber willing to write it for general growth-hormone optimisation is uncommon, and insurers will not fund that use. It also explains why a parallel compounded and research-grade market grew up around the molecule, trading regulatory backing and guaranteed quality for a far lower price. The first route is a fully approved, monitored medicine; the second is not.

Commercially, the EGRIFTA franchise remains the core of Theratechnologies’ business, with the company reporting roughly 19 million US dollars in first-quarter 2025 revenue, up 17% year on year, and positioning Egrifta WR as the driver of future adherence and adoption.

The bottom line: Branded Egrifta exceeds roughly 3,000 dollars a month and is generally covered only for the approved HIV indication.

Tesamorelin is best understood alongside the other growth-hormone secretagogues, which differ sharply in regulatory standing.

• Sermorelin is the shorter GHRH(1-29) fragment and was once an FDA-approved drug before being withdrawn; it is now compounded under section 503A. Tesamorelin and sermorelin are the two GHRH analogues with the most regulatory history, and they are set side by side in our GHRH analogue comparison.
• CJC-1295 is a longer-acting GHRH analogue that was rejected for compounding by the FDA’s advisory committee and has no approved product; its evidence base is far weaker than tesamorelin’s.
• Ipamorelin works through the ghrelin receptor rather than the GHRH receptor, and is the compound most often paired with GHRH analogues in unregulated products.
• MK-677 (ibutamoren) is the non-peptide secretagogue in this family: an oral ghrelin mimetic that, unlike tesamorelin, has never been approved for human use.

For how all of these compounds relate across mechanism, evidence and regulation, see our growth hormone secretagogues overview.

Is tesamorelin FDA approved?

Yes. Tesamorelin was approved by the FDA in 2010 and is the only approved GHRH analogue. It is sold under the brand Egrifta, now in the Egrifta WR formulation, and is indicated only for the reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy.

Is tesamorelin the same as growth hormone?

No. Tesamorelin is a GHRH analogue that stimulates the pituitary to release the body’s own growth hormone in a natural pattern, rather than supplying synthetic growth hormone directly. This preserves the feedback loops that injected growth hormone bypasses.

Can you get tesamorelin for weight loss or anti-ageing?

Not as an approved use. Egrifta is approved only for HIV-associated lipodystrophy, and insurers fund only that indication. Off-label and compounded use exists but lacks regulatory approval, is costly, and has not been studied for general weight loss or anti-ageing.

How much does Egrifta cost?

Branded Egrifta is widely reported to exceed roughly 3,000 US dollars per month without insurance. Coverage is generally limited to the approved HIV-lipodystrophy indication and often needs prior authorisation, though manufacturer assistance programmes can help eligible patients.

Is tesamorelin legal in the UK and Australia?

In the UK, tesamorelin is a prescription-only medicine and Egrifta holds no UK marketing authorisation, so it is supplied only as an unlicensed medicine. In Australia it is a Schedule 4 prescription-only medicine. It is also banned in sport at all times under WADA.

What are the main side effects of tesamorelin?

The most common side effects are joint pain, injection-site reactions, fluid retention and raised blood glucose. It is contraindicated in active malignancy, in disruption of the pituitary axis, and in pregnancy, reflecting the cautions that apply across the growth-hormone axis.